---
name: managing-lipid-therapy
language: en
description: Guides statin selection and intensity with ASCVD risk calculation and LDL targets. Use when managing lipids, calculating cardiovascular risk, or optimizing lipid-lowering therapy.
tags:
  - management
  - cardiology
  - risk
metadata:
  author: casemark
  practice_areas:
    - Cardiology
    - Interventional Cardiology
    - Electrophysiology
  document_types:
    - Management Report
  skill_modes:
    - Management
    - Coordination
---

# Managing Lipid Therapy

Guides statin selection and intensity with ASCVD risk calculation and LDL targets.

## Why This Skill Exists

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death globally. The 2018 AHA/ACC Cholesterol Guideline and 2022 ACC Expert Consensus Decision Pathway define a risk-based approach to lipid management, with LDL-C as the primary target. Landmark trials (4S, HPS, JUPITER, FOURIER, ODYSSEY) demonstrate that each 39 mg/dL reduction in LDL-C reduces major cardiovascular events by approximately 22%.

Despite this, statin therapy remains underutilized — fewer than 50% of eligible patients receive appropriate-intensity statins, and escalation to ezetimibe, PCSK9 inhibitors, or bempedoic acid when LDL remains above target is inconsistent. This skill ensures systematic risk assessment, appropriate statin intensity selection, and evidence-based escalation when targets are not met.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. Does the patient have clinical ASCVD (prior MI, stroke, TIA, PAD, coronary revascularization)? (default: "ASCVD status not documented")
2. What is the fasting lipid panel — TC, LDL-C, HDL-C, triglycerides? (default: "Lipid panel not provided")
3. What is the patient's 10-year ASCVD risk score (Pooled Cohort Equations)? (default: "Not yet calculated")
4. Is the patient currently on lipid-lowering therapy? If so, which agent and dose? (default: "Current therapy not documented")
5. Are there statin-related side effects reported (myalgia, hepatotoxicity, new-onset DM)? (default: "No side effects reported")
6. What are the risk-enhancing factors — family history of premature ASCVD, LDL ≥ 160, metabolic syndrome, CKD, inflammatory conditions, ethnicity, Lp(a), hsCRP? (default: "Risk enhancers not assessed")
7. Has coronary artery calcium (CAC) scoring been performed? (default: "CAC not obtained")
8. Is the patient diabetic? Age range? (default: "Diabetes status not documented")

### Documents to Request

- Fasting lipid panel (recent, within 4–12 weeks of assessment)
- Prior lipid panels for trend analysis
- 10-year ASCVD risk score calculation
- CAC score report if obtained
- Current medication list
- History of statin intolerance documentation
- Lp(a) level if available
- hsCRP if available
- HbA1c (diabetes status)
- Hepatic function panel (baseline before statin initiation)

---

## Step 1: Patient Risk Category Classification

**2018 ACC/AHA Risk Groups:**

| Risk Group | Definition | Primary Therapy |
|-----------|-----------|----------------|
| Clinical ASCVD | Prior MI, stroke, TIA, PAD, coronary revascularization | High-intensity statin; LDL < 70 |
| Very high-risk ASCVD | ASCVD + multiple major events or high-risk conditions | Max statin + ezetimibe ± PCSK9i; LDL < 55 |
| Severe hypercholesterolemia | LDL ≥ 190 mg/dL | High-intensity statin without risk calculation |
| Diabetes (age 40–75) | DM + LDL 70–189 | Moderate-to-high intensity statin based on risk |
| Primary prevention (age 40–75) | No ASCVD, no DM, LDL 70–189 | Based on 10-year ASCVD risk |

**10-Year ASCVD Risk Thresholds (Primary Prevention):**

| Risk Level | 10-Year Risk | Recommendation |
|-----------|-------------|----------------|
| Low | < 5% | Lifestyle; statin generally not indicated |
| Borderline | 5–7.4% | Consider statin if risk enhancers present |
| Intermediate | 7.5–19.9% | Moderate-intensity statin; consider CAC for shared decision-making |
| High | ≥ 20% | High-intensity statin |

**Risk-Enhancing Factors (tip the balance toward statin initiation):**
- Family history of premature ASCVD (♂ < 55, ♀ < 65)
- Persistently elevated LDL ≥ 160 mg/dL
- Metabolic syndrome
- CKD (eGFR 15–59)
- Chronic inflammatory conditions (RA, psoriasis, HIV)
- South Asian ancestry
- Premature menopause (< 40 years)
- Preeclampsia history
- Lp(a) ≥ 50 mg/dL (or ≥ 125 nmol/L)
- hsCRP ≥ 2.0 mg/L
- ABI < 0.9

---

## Step 2: Statin Selection and Intensity

**High-Intensity Statins (≥ 50% LDL reduction):**

| Agent | Dose |
|-------|------|
| Atorvastatin | 40–80 mg |
| Rosuvastatin | 20–40 mg |

**Moderate-Intensity Statins (30–49% LDL reduction):**

| Agent | Dose |
|-------|------|
| Atorvastatin | 10–20 mg |
| Rosuvastatin | 5–10 mg |
| Simvastatin | 20–40 mg |
| Pravastatin | 40–80 mg |
| Lovastatin | 40–80 mg |
| Fluvastatin XL | 80 mg |
| Pitavastatin | 1–4 mg |

**Drug Interactions to Check:**
- Simvastatin: contraindicated with strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors); max 20 mg with amiodarone, amlodipine
- Atorvastatin: dose limit with cyclosporine, clarithromycin, itraconazole
- Rosuvastatin: preferred in patients on CYP3A4 inhibitors (metabolized by CYP2C9)
- All statins: caution with gemfibrozil (rhabdomyolysis risk)

---

## Step 3: LDL-C Target Assessment and Escalation

**LDL-C Targets by Risk Category:**

| Category | LDL-C Target | Threshold for Adding Non-Statin |
|----------|-------------|-------------------------------|
| Very high-risk ASCVD | < 55 mg/dL | LDL ≥ 55 on max statin |
| Clinical ASCVD | < 70 mg/dL | LDL ≥ 70 on max statin |
| High-risk primary prevention (≥ 20%) | ≥ 50% LDL reduction | If not achieving ≥ 50% reduction |
| Diabetes with risk factors | < 70 mg/dL | LDL ≥ 70 on statin |

**Escalation Ladder (add sequentially if LDL not at target):**
1. Maximize statin intensity (atorvastatin 80 mg or rosuvastatin 40 mg)
2. Add ezetimibe 10 mg (additional 15–20% LDL reduction; IMPROVE-IT trial)
3. Add PCSK9 inhibitor: evolocumab 140 mg SC q2 weeks or alirocumab 75–150 mg SC q2 weeks (additional 50–60% LDL reduction; FOURIER, ODYSSEY trials)
4. Consider bempedoic acid 180 mg daily (additional 15–18% LDL reduction; CLEAR Outcomes trial) — particularly useful in statin-intolerant patients
5. Consider inclisiran 284 mg SC (at months 0, 3, then q6 months) for sustained LDL lowering

**Recheck lipid panel 4–12 weeks after any therapy change.**

---

## Step 4: Managing Statin Intolerance

**True vs. Perceived Statin Intolerance:**
- True myopathy: CK elevation > 10× ULN with symptoms → discontinue immediately
- Statin-associated muscle symptoms (SAMS): myalgia without significant CK elevation → most common reason for discontinuation

**Approach to SAMS:**
1. Hold statin for 2–4 weeks (washout)
2. Rechallenge with a different statin at low dose (rosuvastatin 5 mg or pravastatin 20 mg)
3. Try alternate-day dosing (rosuvastatin or atorvastatin — long half-lives permit this)
4. If intolerant to ≥ 2 statins: document as "statin-intolerant"
5. Use non-statin therapies: ezetimibe ± bempedoic acid ± PCSK9i

**CoQ10 supplementation:** Mixed evidence; may consider 100–200 mg daily if patient requests, but not a substitute for rechallenge strategy.

---

## Step 5: Special Populations and Monitoring

**Hypertriglyceridemia Management:**
- TG 150–499 mg/dL: lifestyle + statin (treat ASCVD risk)
- TG ≥ 500 mg/dL: fibrate or omega-3 fatty acids (icosapent ethyl 4 g/day per REDUCE-IT) to prevent pancreatitis
- Icosapent ethyl (Vascepa): indicated for TG 135–499 with ASCVD or diabetes + ≥ 2 risk factors, on statin → 25% RRR for MACE

**Monitoring Schedule:**
| Timepoint | Action |
|-----------|--------|
| Baseline | Fasting lipid panel, hepatic panel, CK if symptomatic, HbA1c |
| 4–12 weeks post-initiation | Fasting lipid panel; hepatic panel if symptomatic |
| Annual (on stable therapy) | Fasting lipid panel; reassess risk factors |
| After any dose change | Fasting lipid panel at 4–12 weeks |

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the patient correctly categorized by ASCVD risk group?
2. Is the statin intensity appropriate for the risk category?
3. Is the LDL-C at target, or is an escalation plan documented?
4. Are risk-enhancing factors documented for borderline/intermediate risk patients?
5. If statin intolerance is claimed, is the rechallenge protocol documented?

---

## Quality Audit

- [ ] Fasting lipid panel documented with date
- [ ] 10-year ASCVD risk score calculated (for primary prevention patients)
- [ ] Risk category assigned per 2018 ACC/AHA guideline
- [ ] Statin intensity matches risk category
- [ ] LDL-C target identified and current level compared
- [ ] Escalation plan documented if LDL not at target
- [ ] Drug interactions checked for statin selection
- [ ] Risk-enhancing factors assessed for borderline/intermediate risk
- [ ] CAC scoring considered for shared decision-making in intermediate risk
- [ ] Statin intolerance properly documented with rechallenge history
- [ ] Hypertriglyceridemia assessed and treated if TG ≥ 500
- [ ] Icosapent ethyl considered for eligible patients (REDUCE-IT criteria)
- [ ] Follow-up lipid panel scheduled at appropriate interval
- [ ] Lifestyle modifications (diet, exercise, weight) reinforced

---

## Guidelines

1. Every ASCVD patient should be on high-intensity statin therapy unless contraindicated — this is the single most impactful pharmacotherapy for secondary prevention.
2. Do not use LDL-C thresholds as the sole criterion for initiating statins in primary prevention — the 10-year ASCVD risk score drives the decision.
3. For patients with LDL ≥ 190 mg/dL, start high-intensity statin without risk calculation — this likely represents familial hypercholesterolemia.
4. CAC score of 0 in intermediate-risk patients supports deferring statin therapy (low event rate) — but does not apply to patients with diabetes, ASCVD, or LDL ≥ 190.
5. PCSK9 inhibitors provide large LDL reductions but should be reserved for patients who cannot reach target on maximally tolerated statin + ezetimibe — document prior authorization requirements.
6. Statin intolerance requires objective documentation: ≥ 2 statin trials, symptom recurrence with rechallenge, and symptom resolution with discontinuation. Nocebo effect is common.
7. Routine CK monitoring in asymptomatic patients on statins is not recommended — check only if muscle symptoms develop.
8. Omega-3 fish oil supplements (non-prescription) do not have cardiovascular benefit at standard doses — only icosapent ethyl 4 g/day (prescription EPA) has trial-proven benefit.